{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:59:14Z","timestamp":1780984754978,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004206","name":"The University of Osaka","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10067-026-08061-7","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:51:36Z","timestamp":1775026296000},"page":"3101-3109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes of molecular-targeted therapies for rheumatoid arthritis: comparison between orthopaedic surgeons and rheumatologists in the multicenter retrospective ANSWER cohort"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5741-5969","authenticated-orcid":false,"given":"Yuki","family":"Etani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3620-8412","authenticated-orcid":false,"given":"Yasutaka","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6958-2983","authenticated-orcid":false,"given":"Kohei","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9938-6780","authenticated-orcid":false,"given":"Takaaki","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-3937","authenticated-orcid":false,"given":"Koichi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-1226","authenticated-orcid":false,"given":"Takayuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4668-1718","authenticated-orcid":false,"given":"Iku","family":"Shirasugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0590-6584","authenticated-orcid":false,"given":"Mai","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3183-4193","authenticated-orcid":false,"given":"Koji","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-1295","authenticated-orcid":false,"given":"Ayaka","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-060X","authenticated-orcid":false,"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8849-9824","authenticated-orcid":false,"given":"Tadashi","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2810-1519","authenticated-orcid":false,"given":"Yuji","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9991-4176","authenticated-orcid":false,"given":"Tetsu","family":"Itami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7244-7715","authenticated-orcid":false,"given":"Yonsu","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiko","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-4221","authenticated-orcid":false,"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4749-7117","authenticated-orcid":false,"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5107-8209","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8964-4229","authenticated-orcid":false,"given":"Ken","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1024","authenticated-orcid":false,"given":"Kosuke","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"8061_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/JIR.S219586","volume":"13","author":"R Harrington","year":"2020","unstructured":"Harrington R, Al Nokhatha SA, Conway R (2020) Jak inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res 13:519\u2013531","journal-title":"J Inflamm Res"},{"issue":"8","key":"8061_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40265-024-02059-8","volume":"84","author":"EG Favalli","year":"2024","unstructured":"Favalli EG, Maioli G, Caporali R (2024) Biologics or janus kinase inhibitors in rheumatoid arthritis patients who are insufficient responders to conventional anti-rheumatic drugs. Drugs 84(8):877\u2013894","journal-title":"Drugs"},{"issue":"1","key":"8061_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8061_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/mr\/roaf006","volume":"35","author":"M Harigai","year":"2025","unstructured":"Harigai M, Kaneko Y, Tanaka E, Hirata S, Kameda H, Kaneko K et al (2025) 2024 update of the Japan college of rheumatology clinical practice guidelines for the management of rheumatoid arthritis: secondary publication. Mod Rheumatol 35(3):387\u2013401","journal-title":"Mod Rheumatol"},{"issue":"2","key":"8061_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3109\/s10165-011-0495-7","volume":"22","author":"S Momohara","year":"2012","unstructured":"Momohara S, Inoue E, Ikari K, Yano K, Tokita A, Honjo Y et al (2012) Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute. Mod Rheumatol 22(2):209\u201315","journal-title":"Mod Rheumatol"},{"issue":"1","key":"8061_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","volume":"30","author":"H Yamanaka","year":"2020","unstructured":"Yamanaka H, Tanaka E, Nakajima A, Furuya T, Ikari K, Taniguchi A et al (2020) A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options. Mod Rheumatol 30(1):1\u20136","journal-title":"Mod Rheumatol"},{"issue":"1","key":"8061_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/rheumatology\/keq209","volume":"50","author":"KL Hyrich","year":"2011","unstructured":"Hyrich KL, Watson KD, Lunt M, Symmons DP (2011) Changes in disease characteristics Hyrich KL, Watson KD, Lunt M, Symmons DP. Changes in disease characteristics Hyrich KL, Watson KD, Lunt M, Symmons DP. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) 50(1):117\u201323","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"8061_CR8","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/mr\/roab043","volume":"32","author":"K Murata","year":"2022","unstructured":"Murata K, Uozumi R, Hashimoto M, Ebina K, Akashi K, Onishi A et al (2022) The real-world effectiveness of anti-RANKL antibody denosumab on the clinical fracture prevention in patients with rheumatoid arthritis: the ANSWER cohort study. Mod Rheumatol 32(4):834\u2013838","journal-title":"Mod Rheumatol"},{"issue":"4","key":"8061_CR9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/mr\/roac092","volume":"33","author":"K Ebina","year":"2023","unstructured":"Ebina K, Hirano T, Maeda Y, Okita Y, Etani Y, Hirao M et al (2023) Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: the ANSWER cohort study. Mod Rheumatol 33(4):690\u2013699","journal-title":"Mod Rheumatol"},{"issue":"5","key":"8061_CR10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/mr\/roac115","volume":"33","author":"H Makino","year":"2023","unstructured":"Makino H, Kotani T, Hata K, Nishioka D, Yamamoto W, Yoshikawa A et al (2023) Prognostic factors affecting respiratory-related death in patients with rheumatoid arthritis complicated by interstitial lung disease: an ANSWER cohort study. Mod Rheumatol 33(5):928\u201335","journal-title":"Mod Rheumatol"},{"issue":"5","key":"8061_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/mr\/roaf029","volume":"35","author":"Y Etani","year":"2025","unstructured":"Etani Y, Okita Y, Maeda Y, Tsujimoto K, Hirao M, Onishi A et al (2025) Distinct impact of RF and ACPA titre on the effectiveness and persistency of biologics and JAK inhibitors: the ANSWER cohort study. Mod Rheumatol 35(5):820\u20139","journal-title":"Mod Rheumatol"},{"issue":"3","key":"8061_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u201324","journal-title":"Arthritis Rheum"},{"key":"8061_CR13","doi-asserted-by":"crossref","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases. 69(9):1580\u20138","DOI":"10.1136\/ard.2010.138461"},{"key":"8061_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003160","author":"K Ebina","year":"2023","unstructured":"Ebina K, Etani Y, Maeda Y, Okita Y, Hirao M, Yamamoto W et al (2023) Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2023-003160","journal-title":"RMD Open"},{"issue":"9","key":"8061_CR15","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","volume":"53","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Biggioggero M, Marchesoni A, Meroni PL (2014) Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology 53(9):1664\u20131668","journal-title":"Rheumatology"},{"key":"8061_CR16","doi-asserted-by":"crossref","unstructured":"Gabay C, Riek M, Scherer A, Finckh A, physicians obotSc (2015) Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology. 54(9):1664\u201372","DOI":"10.1093\/rheumatology\/kev019"},{"issue":"12","key":"8061_CR17","first-page":"2156","volume":"54","author":"TS J\u00f8rgensen","year":"2015","unstructured":"J\u00f8rgensen TS, Kristensen LE, Christensen R, Bliddal H, Lorenzen T, Hansen MS et al (2015) Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. Rheumatology 54(12):2156\u201365","journal-title":"Rheumatology"},{"issue":"1","key":"8061_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02232-w","volume":"22","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K et al (2020) Drug retention of 7 biologics and tofacitinib in biologics-na\u00efve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther 22(1):142","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"8061_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"8061_CR20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, Buch M, Burmester G, Dougados M et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492\u2013509","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8061_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, van der Goes MC et al (2021) EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 80(1):31\u20135","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08061-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08061-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08061-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:25:10Z","timestamp":1780982710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08061-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8061"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08061-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The representative facility for this registry was Kyoto University. This observational study was conducted following the Declaration of Helsinki and approved by the ethics committees of the following seven institutes: Kyoto University (granted on 2016-03-24\/approval No. R053), Osaka University (granted on 2015-11-04\/approval No. 15300), Osaka Metropolitan University (granted on 2021-6-09\/approval No. 2021-074), Osaka Medical and Pharmaceutical University (granted on 2014-07-14\/approval No. 1529), Kansai Medical University (granted on 2017-11-21\/approval No. 2014625), Kobe University (granted on 2015-03-20\/approval No. 1738), Nara Medical University (granted on 2018-01-23\/approval No. 1692), and Osaka Red Cross Hospital (granted on 2015-09-01\/approval No. 644). Written informed consent was obtained from the participants. The ethics committee at Osaka University Hospital waived the requirement for patient informed consent by posting the opt-out information on the hospital\u2019s homepage.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Written informed consent to publish the study results was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y.E. and K.E. are affiliated with the Department of Sports Medical Biomechanics, The University of Osaka Graduate School of Medicine Faculty of Medicine, which is supported by Asahi-Kasei.Y.E. has received a speaker fee from Amgen, Asahi-Kasei, Ayumi, Daiichi-Sankyo, Eisai, Taisho, and UCB Japan. Y.O. has received speaker fees from Eli Lilly, Nippon Boehringer Ingelheim, Pfizer, Asahi-Kasei, Ono Pharmaceutical, Mitsubishi-Tanabe, Taisho, and Novartis Pharma. K.M. is affiliated with a department that is financially supported by two pharmaceutical companies (Asahi- Kasei and Ayumi) and the city government (Nagahama City) and received a research grant from Daiichi-Sankyo and a speaker fee from AbbVie, Asahi-Kasei, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, Bristol-Myers Squibb, and Pfizer. T.F. is affiliated with a department that is financially supported by two pharmaceutical companies (Asahi-Kasei and Ayumi) and the city government (Nagahama City) and has received a speaker fee from Asahi-Kasei, AbbVie, Janssen, Mitsubishi-Tanabe, and Eisai. M.H. has received research grants and\/or a speaker fee from Asahi Kasei, Astellas, AstraZeneca, Ayumi Pharma, Brystol Meyers, Chugai, Eisai, Eli Lilly, Gilead Sciences Japan, Janssen pharma, Ono Pharma, Ohtsuka Pharma, Taisho Pharma, Tanabe Mitsubishi, UCB Japan. T.O. received a research grant from AbbVie, Asahi-Kasei, Chugai, Eisai, Eli Lilly and Mitsubishi-Tanabe and a speaker fee from AbbVie, Chugai, Eli Lilly, Janssen, and Novartis Pharma. T.K. is affiliated with a department that is financially supported by six pharmaceutical companies (Mitsubishi-Tanabe, Asahi-Kasei, AbbVie, Chugai, Eisai, and Takeda) and has received payments for lectures from AbbVie, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Pfizer, and Boehringer Ingelheim. Y.N. has received speaker fees from Astellas Pharma, Asahi Kasei Pharma, Eisai, Eli Lilly, AstraZeneca, and Tanabe Pharma. Y.S. has received speaking fees from Pfizer, Chugai., Janssen Pharmaceutical K.K., Eisai, and AbbVie. A.K. has received a research grant from Chugai and a speaker fee from Chugai, Eisai, Mitsubishi-Tanabe, AbbVie, and Ono Pharmaceutical.K. Nakata. has received a research grant from Astellas and supervises the Department of Sports Medical Biomechanics, The University of Osaka Graduate School of Medicine Faculty of Medicine, which is supported by Asahi-Kasei. K.E. has received research grants from Asahi-Kasei and Teijin Pharma. K.E. has received a speaker fee from AbbVie, Amgen, Argenx, Asahi-Kasei, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Ono Pharmaceutical, Pfizer, Sanofi, Taisho, Teijin Pharma, and UCB Japan. The remaining authors have declared no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}